Copenhagen, December 15
th, 2020
GreenMobility receives approvals for admission to trading and official listing on Nasdaq Copenhagen Main Market and deletion from Nasdaq First North Growth Market Denmark
With reference to company announcement no. 69 dated 7 October 2020 and no. 74 dated 11 December 2020, GreenMobility A/S (“GreenMobility”) today announces that it has received the following approvals from Nasdaq Copenhagen regarding:
application for admission of GreenMobility’s shares to trading and official listing on Nasdaq Copenhagen Main Market subject to the Danish Financial Supervisory Authority’s approval of and subsequent publication by GreenMobility of a listing prospectus.
application for deletion of GreenMobility’s shares from trading on Nasdaq First North Growth Market Denmark subject to and conditional upon the admission of the Company’s shares to trading and official listing on Nasdaq Copenhagen Main Market following the publication of a listing pro
Nexstim Oyj: Nexstim Plc Annuls Stock Options Held by the Company
Nexstim Plc Annuls Stock Options Held by the Company
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that its Board of Directors has resolved in its meeting on 15.12.2020 on annulment of in total 3,108 option rights 2016B; in total 65,827 option rights 2016C; in total 33,888 option rights 2018A; and in total 33,888 option rights 2018B which are in the possession of the Company or have been returned to the possession of the Company due to ended employments.
Pursuant to the annulment, no option rights in those plans remain in the possession of the Company. The Board of Directors of the Company also resolved on annulment of all option rights in the stock option plan 2017 which have been returned to the possession of the Company due to an ended employment and resolved on termination of the stock option plan 2017.
Share:
STOCKHOLM, Dec. 15, 2020 /PRNewswire/
Cyxone (publ.), a clinical stage biotech company developing first-in-class drugs for diseases of the immune system, announced today that the company has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) pertaining to its drug candidate Rabeximod. The application follows on a productive pre-IND meeting with the authority, where valuable advice was received on
inter alia
the protocol for its imminent European Phase 2 clinical study in moderate Covid-19. The IND covers the development of Rabeximod in Covid-19 and other indications, such as rheumatoid arthritis, and is a prerequisite for a future validation of the company s five recent patent applications in the US market.
Effnet has launched its latest release of Effnet ROHC portfolio and 3GPP defined Ethernet Header Compression, EHC
December 15, 2020 04:01 ET | Source: Effnetplattformen AB (publ) Effnetplattformen AB (publ) Luleå, SWEDEN
Luleå, 2020-12-15 Effnet AB, a subsidiary of Effnetplattformen AB and the premier provider of header compression software for wireless and fixed networks today announced that it has launched its latest release of the Effnet ROHC portfolio on reaching a significant milestone in its continuous work on performance optimization.
This latest release has been proven on a wide variety of platforms including ARM Cortex-M series suitable for IoT devices, Cortex-A series suitable for smartphone as well as base-station type of products and x86 processors for high user/bandwidth capacity network systems. The Effnet ROHC portfolio scales very well across these platforms and applications due to its optimized memory and
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;